RCM
ENTA icon

RA Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

RA Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,038,000
Closed -$5.97M – 90
2024
Q4 		$5.97M Buy
+1,038,000
New +$9.95M 0.08% 82
2022
Q4 		– Sell
-896,724
Closed -$46.5M – 74
2022
Q3 		$46.5M Hold
896,724
– – 0.99% 33
2022
Q2 		$42.4M Sell
896,724
-67,488
-7% -$3.66M 1.13% 30
2022
Q1 		$68.6M Buy
+964,212
New +$62.7M 1.5% 18
2014
Q4 		– Sell
-250,000
Closed -$9.89M – 54
2014
Q3 		$9.89M Sell
250,000
-1,289,586
-84% -$51.4M 1.17% 22
2014
Q2 		$66.3M Sell
1,539,586
-1,492
-0.1% -$56.9K 6.7% 5
2014
Q1 		$61.6M Buy
+1,541,078
New +$56M 4.42% 10
2013
Q3 		– Sell
-436,145
Closed -$7.72M – 40
2013
Q2 		$7.72M Buy
+436,145
New +$8.5M 1.02% 20

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RA Capital Management's ENTA Position: Q1 2025 in Review

RA Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 1,038,000 shares — an estimated $5.97M sold.

RA Capital Management first reported a position in ENTA in Q2 2013 and held it in 8 quarters. The position peaked at $68.6M in Q1 2022. 110 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.

  • RA Capital Management reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • RA Capital Management sold 1,038,000 Enanta Pharmaceuticals shares in Q1 2025, an estimated $5.97M.
  • RA Capital Management first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • RA Capital Management's Enanta Pharmaceuticals position peaked at $68.6M in Q1 2022.
  • 110 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.